好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Corticosteroids affect the dynamics of multiple sclerosis lesions formation
Multiple Sclerosis
P3 - Poster Session 3 (5:30 PM-6:30 PM)
15-079

To obtain in-vivo evidence of early dynamics of multiple sclerosis (MS) lesions formation and changes that corticosteroids may induce.

MRI showed that the development of MS lesions is dynamic and heterogeneous. Lesions grow outward from a central vein comprising disruption of the blood-brain-barrier (BBB) illustrated in the centrifugal enhancement proved by dynamic contrast–enhanced (DCE) MRI; in some of them, a substantial immune reaction at the edge of the lesion, opens the BBB in the capillaries mirrored as the centripetal enhancement by DCE. The latter, previously called ring-like, are associated with more severe tissue damage and may show a paramagnetic-rim, which persistency may represent failure of lesion repair and in later stages, smoldering lesions.

Six relapsing patients were scanned in a General Electric 3.0 tesla scanner. T2-weighted, susceptibility-weighted, T1-weighted (before/after gadolinium), and DCE scans were acquired at baseline, days 5, 10 and 30 post-exacerbation. Half of the patients were infused with methylprednisolone 1000mg/5days, immediately after baseline MRI.For each enhancing-lesion, dynamic of enhancement, size, and phase appearance, were assessed at each time-point.

Fifty-seven lesions were analyzed; centrifugal lesions (n=45) were smaller (4.5mm) than 15 centripetal ones (10.5mm); eight centripetal showed a paramagnetic-rim. Three patients not treated with corticosteroids developed 19 lesions, 8/9(88%) at baseline were centrifugal (1 centripetal); at day 30, 7/9(70%) lesions were centripetal (2 centrifugal). Three patients treated with methylprednisolone had 38 lesions, 28/31(90%) at baseline were centrifugal (3 centripetal), most of enhancement transiently or definitely disappeared at second time-point. At day 30, 3/11 were centripetal (27%) (8 centrifugal). 

Corticosteroids seem to be effective for closing transiently/definitely the BBB of most active lesions and notably for preventing the shift to centripetal enhancement, probably eluding the stronger immune reaction at the edge of the developing lesion.This may portend less chronic tissue damage.

Authors/Disclosures
Maria Gaitan
PRESENTER
Maria Gaitan has received personal compensation in the range of $500-$4,999 for serving as a has received reimbursement for developing educational presentations and/or travel/accommodations stipends from with Merck SA, Merck-Serono Argentina, Biogen-Idec Argentina, Novartis Argentina, Roche Argentina,.
No disclosure on file
Maria C. Ysrraelit No disclosure on file
No disclosure on file
No disclosure on file
Jorge D. Correale, MD (Institute for Neurological Research) Dr. Correale has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Correale has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Correale has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Correale has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Correale has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Correale has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROche. Dr. Correale has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Correale has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Correale has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Correale has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. The institution of Dr. Correale has received research support from Merck. The institution of Dr. Correale has received research support from Biogen. The institution of Dr. Correale has received research support from Novartis .